TIF
Issue 62 – March 2013
Latest News:
- Chiesi Group and Apotex Inc. finalize agreement for the acquisition of Ferriprox® (Deferiprone)
- Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany
- Deferasirox Accord: A new generic of Exjade recommended for approval by the EMA
- FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
- Thalassaemia Month of Banyumas 2019 -“Banyumas Goes to Zero Growth of Thalassaemia 2023”
